# DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE
> **ANDA210811** · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA LIMITED · Approved 2025-06-12
## Drug
- **FDA Application Number:** ANDA210811
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE
- **Generic name:** Abacavir || Dolutegravir || Lamivudine
- **Active ingredients:** ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
- **Dosage form:** TABLET
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** CIPLA LIMITED
- **First approval:** 2025-06-12
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210811)
---
*MORVS · CC0 1.0*